Gene: SLC35C2
Official Full Name: solute carrier family 35 member H1provided by HGNC
Gene Summary: This gene encodes a member of the triose-phosphate transporter protein family. This gene is regulated by oxygen tension, is induced in hypoxic trophoblast cells, and is overexpressed in ovarian cancer. Alternative splicing results in multiple transcript variants. A pseudogene of this gene has been defined on the X chromosome. [provided by RefSeq, Jul 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO23208 | SLC35C2 Knockout cell line (HeLa) | Human | SLC35C2 | 1:3~1:6 | Negative | Online Inquiry |
KO23209 | SLC35C2 Knockout cell line (HCT 116) | Human | SLC35C2 | 1:2~1:4 | Negative | Online Inquiry |
KO23210 | SLC35C2 Knockout cell line (HEK293) | Human | SLC35C2 | 1:3~1:6 | Negative | Online Inquiry |
KO23211 | SLC35C2 Knockout cell line (A549) | Human | SLC35C2 | 1:3~1:4 | Negative | Online Inquiry |
SLC35C2 Gene Knockout Cell Lines are specialized cellular models that have been engineered to lack functional SLC35C2 genes, which play a crucial role in nucleotide sugar transport. These knockout cell lines provide researchers with an invaluable tool for investigating the biological functions of SLC35C2 and its associated pathways in various physiological and pathological contexts. By disrupting the expression of this gene, scientists can examine the effects on glycosylation processes, cellular metabolism, and overall cellular behavior, leading to a greater understanding of the role SLC35C2 plays in disease mechanisms such as cancer and metabolic disorders.
The key mechanism of action of the SLC35C2 knockout involves the consequent alterations in nucleotide sugar availability, impacting glycosylation reactions critical for protein function and cellular signaling. This cellular model enables detailed studies on the downstream effects of disrupted glycosylation patterns, facilitating insights into the roles of SLC35C2 in health and disease.
In the context of scientific research and clinical applications, these knockout cell lines offer significant relevance. They can be employed to explore drug responses, identify potential therapeutic targets, and validate biomarkers in various diseases. Researchers can leverage these models to unveil new therapeutic strategies that mitigate the effects of altered glycosylation brought about by SLC35C2 loss, which is particularly valuable in cancer research.
Compared to alternative cell lines that may express SLC35C2, the knockout versions provide unambiguous insights into gene function without confounding effects. This specificity enhances experimental accuracy, making these cell lines critical assets for rigorous scientific investigations.
For researchers and clinicians focused on elucidating the intricacies of glycosylation and its impact on disease, SLC35C2 Gene Knockout Cell Lines represent a pioneering resource. They offer a unique opportunity to further our understanding of molecular biology and improve therapeutic strategies. With our robust expertise in cellular models and genetic engineering, we ensure that our products meet the highest standards of quality and reliability, empowering scientists to advance their research with confidence.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.